HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Selegiline (E250)

A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

Also Known As:

E250; Jumex; E 250; Deprenyl; E-250; Eldepryl; Bristol-Myers Squibb Brand of Selegiline; Emsam; Humex; L-Deprenyl; Selegiline Hydrochloride; Selegiline Hydrochloride, (R)-Isomer; Selegiline Hydrochloride, (R,S)-Isomer; Selegiline Hydrochloride, (S)-Isomer; Selegiline, (R)-Isomer; Selegiline, (R,S)-Isomer; Selegiline, (S)-Isomer; Selegyline; Valeant Brand of Selegiline; Yumex; Zelapar; Bristol Myers Squibb Brand of Selegiline; Hydrochloride, Selegiline; Selegiline Valeant Brand; Deprenalin; Deprenil; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-

Networked: 862 relevant articles (93 outcomes, 214 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Amines: 1422
  - Ethylamines: 5
    - Phenethylamines: 14
      - Selegiline: 862
        deprenyl-N-oxide: 2
        N-Methyl,N-propargyphenylethylamine: 1
        selegiline-N-oxide: 1
        4-fluorodeprenyl
        p-fluoro-L-deprenyl

Experts

1.	Magyar, Kálmán: 10 articles (05/2013 - 02/2002)
2.	Parkinson Study Group DATATOP Investigators: 8 articles (03/2015 - 04/2008)
3.	Youdim, Moussa B H: 7 articles (01/2010 - 04/2002)
4.	Magyar, K: 6 articles (01/2014 - 01/2000)
5.	Riederer, P: 6 articles (03/2004 - 01/2000)
6.	Auinger, Peggy: 5 articles (03/2015 - 01/2011)
7.	Müller, Thomas: 5 articles (10/2014 - 05/2002)
8.	Szende, B: 5 articles (06/2010 - 01/2000)
9.	Amsterdam, Jay D: 5 articles (01/2008 - 11/2002)
10.	Maruyama, W: 5 articles (01/2007 - 01/2000)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 05/01/2003 - "Deprenyl and other propargylamines are clinically beneficial in Parkinson's disease (PD). " 01/01/1986 - "Overall, (-)deprenyl was effective in the treatment of our parkinsonian patients in the various conditions evaluated, and thus constitutes a new therapeutic strategy for Parkinson's disease." 01/01/1987 - "It has recently been suggested that deprenyl might be effective in altering the course of Parkinson's disease by actually slowing its progression. " 02/01/2011 - "Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease." 03/07/2006 - "R-(-)-Deprenyl (deprenyl) ameliorates the progression of disability in early Parkinson's disease and also has neuroprotective actions. "
2.	Alzheimer Disease (Alzheimer's Disease) 09/01/1992 - "Maintenance on (-)deprenyl significantly improved the performance of patients with Alzheimer's disease. " 01/01/2003 - "The efficacy of selegiline for symptoms of Alzheimer's disease remains controversial and is reflected by its low rate of prescription and the lack of approval by several regulatory authorities in Europe and elsewhere. " 01/01/2000 - "The efficacy of selegiline for symptoms of Alzheimer's disease remains controversial and is reflected by its low rate of prescription and the lack of approval by several regulatory authorities in Europe and elsewhere. " 11/01/2006 - "In Alzheimer's disease, short term studies of selegiline suggest a beneficial effect; whereas long term studies are less convincing." 02/01/2002 - "The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials."
3.	Parkinsonian Disorders (Parkinsonism) 01/01/1987 - "Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism." 01/01/1993 - "These results show that selegiline is safe and effective as monotherapy in early parkinsonism. " 01/01/1993 - "The French Selegiline Multicenter Trial was carried out in 1990 to investigate whether the disability of de novo patients with parkinsonism could be improved during the first 3 months by monotherapy with selegiline (10 mg/day). " 03/01/2015 - "Subjects were drawn from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study, a large clinical trial that enrolled initially untreated PD patients. " 05/01/2011 - "The Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism trial pioneered the use of functional clinical end points, utilized a 2 × 2 factorial design to more efficiently analyze multiple interventions, and employed a washout design to assist in sorting putative neuroprotective from symptomatic effects. "
4.	Major Depressive Disorder (Major Depressive Disorders) 07/01/2009 - "Selegiline transdermal system is safe and effective in treating major depressive disorder at the dose range of 6 - 12 mg/24 h, without the need for dietary precautions at the 6 mg/24 h dose. " 07/01/2009 - "Selegiline transdermal system: a novel treatment option for major depressive disorder." 02/01/2003 - "A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder." 11/01/2013 - "Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed." 01/01/2013 - "Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report."
5.	Neurodegenerative Diseases (Neurodegenerative Disease) 11/01/2006 - "Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases." 03/01/2002 - "Prophylactic use of low doses of l-deprenyl may accord protection against vascular and neurodegenerative diseases associated with aging." 07/15/1998 - "L-deprenyl protects neurons in a number of in vivo and in vitro models and it has been postulated that it ameliorates some neurodegenerative disorders. " 09/01/2011 - "This study suggests the potential use of combined selegiline and stem cell therapy to improve deficits in neurodegenerative diseases." 01/01/2006 - "This study suggests the potential use of combined selegiline and stem cell therapy to improve deficits in neurodegenerative diseases in aging."

Related Drugs and Biologics

1.	Monoamine Oxidase (MAO)
2.	Selegiline (E250)
3.	Levodopa (L Dopa)
4.	rasagiline (Azilect)
5.	Vitamin E
6.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
7.	Bromocriptine (Parlodel)
8.	Tablets
9.	Norepinephrine (Noradrenaline)
10.	levodopa drug combination carbidopa (Nakom)

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Sympathectomy (Sympathectomies)
4.	Drug Therapy (Chemotherapy)
5.	Injections